Aim There is a lack of an overview of the factors associated with postacute COVID‐19 musculoskeletal symptoms. The aims of this study were as follows: 1‐ to evaluate the most frequent admission symptoms and the frequency of musculoskeletal symptoms in postacute COVID‐19 patients; and 2‐ to determine the related factors with the postacute COVID‐19 musculoskeletal symptoms. Methods A total of 280 postacute COVID‐19 patients (183 females, 97 males) were enrolled and divided into two groups: 1‐ patients whose musculoskeletal symptoms initiated with or were aggravated by COVID‐19 (n = 240); and 2‐ patients whose musculoskeletal symptoms did not change with COVID‐19 (n = 40). The variables were demographic and treatment data, symptoms on admission, postacute COVID‐19 symptoms, laboratory results (complete blood count, erythrocyte sedimentation rate, C‐reactive protein, ferritin and d ‐dimer), chest computed tomography findings and symptoms during acute COVID‐19. Results Most of the patients have fatigue (71.8%), spine pain (70.7%) and myalgia (60.7%). The most common pain region was the back (30.4%). The frequency of dyspnoea was 30%, cough 18.5% and chest pain 10.7%. Having any chronic disease ( P = .031), the duration of hospital stay ( P = .016), frequency of back pain during acute COVID‐19 ( P = .018), tomography findings and d ‐dimer ( P = .035) levels were significantly higher, and lymphocyte ( P = .024) levels were significantly lower in the patients whose symptoms began with or were aggravated by COVID‐19. Conclusion Back pain was the most frequent symptom on admission. The most common postacute COVID‐19 musculoskeletal symptoms were fatigue, spine pain and myalgia. Lower lymphocyte and higher d ‐dimer levels, the presence of COVID‐19 findings in tomography and back pain during acute COVID‐19 infection, higher duration of hospital stay and having chronic diseases were related to post‐COVID‐19 musculoskeletal symptoms.

No abstract

No abstract

The aim of this study is to compare the effect of glycemic control on both inflammatory parameters and vitamin levels in both rheumatoid arthritis and fibromyalgia. A total of 76 patients with type 2 diabetes mellitus and rheumatoid arthritis and 76 patients with type 2 diabetes mellitus and fibromyalgia were retrospectively evaluated in terms of the levels of 25 hidroxy vitamin D, vitamin B12, ferritin, folic asit, erythrocyte sedimentation rate, C-reactive protein, fasting blood glucose, hemoglobin A1c and complete blood count. C-reactive protein, ratios of platelet to lymhocyte and neutrophil to lymhocyte (p<0.001) and erythrocyte sedimentation rate (p=0.002) were significantly higher in patients with rheumatoid arthritis. However hemoglobin A1c, fasting glucose level, monocyte to lymhocyte ratio and vitamin levels were similar between patients with rheumatoid arthritis and fibromyalgia. Both groups were divided into two groups according to hemoglobin A1c being higher or lower than 7%. C-reactive protein (p=0.037) and monocyte to lymhocyte ratio (p=0.050) were significantly higher in rheumatoid arthritis patients with hemoglobin A1c≥7% than hemoglobin A1c<7%. However no significant difference was found in any parameter in fibromyalgia patients according to the level of hemoglobin A1c. Our study results showed that the levels of hemoglobin A1c was similar in patients with rheumatoid arthritis and fibromyalgia. And poor glycemic control accelerates inflammation in only rheumatoid arthritis, however it does not seem to effect vitamin levels.

The aim of the present study was to assess the efficacy of low level laser therapy (LLLT) combined with thumb support wirst splint in patients with de Quervain's tenosynovitis and to investigate whether the thumb support wirst splint combined with LLLT is superior to splint-alone. Thirty-five female patients with a positive Finkelstein test and radial styloid tenderness were included in this study. Patients were divided two group. Patients in group 1(n=18) were applied LLLT combined thumb support wirst splint and patients in group 2 (n=17) wore thumb support wirst splint-only. Patients were instructed to use one splint full time for a period of 3 weeks. LLLT was applied five times a week, for a total of 15 sessions. Visual analog scale (VAS), grip-strength, and global improvement as reported on a verbal scale (VSGI) were used for evaluations. Clinical evaluations were performed at baseline and at the end of the treatment. Before the treatment, clinical parameters were similar between the treatment groups. Posttreatment VAS significantly improved in both groups compared to the pretreatment values (group 1; p<0.001, group 2; p=0.016). Grip strength and VSGI only improved in group 1 after treatment (p=0.020, p<0.001). There was no posttreatment difference in any parameter when the groups were compared with each other (p> 0.05). As a result of this study, it is found that there is no difference between groups in the treatment of De Quervain's tenosynovitis. It has been thought that both treatment methods provide symptomatic relief.